Two awards for Sensimed

From 15^th to 19^th April, 2015 Sensimed was exhibiting during the 43^rd International Exhibition of Inventions of Geneva. At this occasion various prizes were given to the inventors by an International Jury of 85 people. Among more than 1000 inventions, the company has been awarded with two prizes:

• The International Press prize results from the vote of the journalists present during the event;
• The Gold medal of the Medicine & Healthcare category has been given with congratulations of the jury.

Sensimed had the opportunity to exhibit during this show following the award received end of December 2014 at the competition “ID Inventer Demain” rewarding the Swiss French innovative entrepreneur of the year organized by Swiss and French television channels RTS and France 3. The innovation awarded, is SENSIMED Triggerfish®, a contact lens based medical device which contributes to improve the disease management of glaucoma patients. This unique system is designed to record ocular dimensional changes related to intraocular pressure during a 24 hour period.

“It is a real honor to receive these two prizes. We were surprised to have such a success among more than 1000 other great inventions.” says Matteo Leonardi, co-founder of Sensimed. “These prizes represent another encouraging step for all Sensimed team and will give us additional visibility among future investors.”

Sensimed has developed a unique non-invasive soft contact lens-based solution, the SENSIMED Triggerfish, with the aim of revolutionizing glaucoma management by providing an automated recording of continuous ocular dimensional change over 24 hours.

The Company is now focused on expanding the knowledge of how this individual data can best be used in the clinical setting to deliver customized treatment. The 24 hour profiles are being centralized on a registry together with patient and treatment information. The data is being analyzed and modeled on an ongoing basis in an attempt to identifying pathological patterns that can be used to differentiate indication, personalize treatment and assess efficacy following treatment.